Tigermed's November 2025 share capital remains stable, A-share buybacks noted

Hangzhou Tigermed Consulting's November 2025 monthly statement indicates stable statutory/registered share capital for both its A-shares and H-shares. The company's A-share statutory/registered capital remained at RMB 737,901,250, corresponding to 737,901,250 shares at a par value of RMB 1 per share. Its H-share statutory/registered capital stood at RMB 123,124,800, representing 123,124,800 shares with a par value of RMB 1 per share. The total statutory/registered share capital at the end of November 2025 was RMB 861,026,050.

Regarding issued shares, the number of issued A-shares (excluding treasury shares) remained 732,017,470, with 5,883,780 A-shares held as treasury shares, totaling 737,901,250 A-shares. The issued H-shares also remained unchanged at 123,124,800. No increases or decreases were reported for either A-shares or H-shares during November 2025.

The company provided a note detailing A-share repurchases that occurred between May 2024 and February 2025. A total of 3,922,520 treasury A-shares were cancelled on May 29, 2025. As of November 30, 2025, Hangzhou Tigermed Consulting held 5,883,780 A-shares as treasury stock.